According to a study that was published in the New England Journal of Medicine, this class of drugs did not increase the risk for cardiovascular events, which was previously discussed and a concern in the medical community.
Sam Grossman provides some information on the recently approved 200 unit/mL formulation of Eli Lilly and Company’s pre-filled pen containing insulin lispro (Humalog U-200 KwikPen).
The U.S. Food and Drug Administration (FDA) recently announced that sodium-glucose cotransporter-2 (SGLT2) inhibitors may be linked to cases of increased levels of acid in the blood. Sam Grossman talks about the FDA’s reporting on this subject.
Genentech’s drug Avastin is used to treat cancer, but has also been used off-label for treatment of eye disease including diabetic retinopathy (DR). Sam Grossman discusses some of the studies’ findings of this medicine and whether people with DR may want to inquire with their healthcare providers about it.
Certified diabetes educator Amy Hess-Fischl talks about using GLP-1 agonists off-label in people with type 1 and shares some anecdotal evidence from patients as well as studies using this drug class in this patient population.
The Prevent Diabetes STAT: Screen, Test, Act–Today initiative and National Diabetes Prevention Program (NDPP) Lifestyle Change Programs are essential to stem the rising tide of diabetes.
An FDA Panel recommends new safety information on DPP-4 inhibitors Onglyza and Nesina. Sam Grossman reviews this news and how it may affect marketing and prescribing of the medications.
Sanofi’s recently approved insulin, Toujeo, is 300u/ml and offers clinicians and people with diabetes who have glycemic control issues another long-acting insulin. Sam Grossman discusses some of the studies’ findings.
The Dario glucose meter provides high functionality and numerous features to help make the life of people with diabetes easier. Andrew Stivelman reviews this high tech device and app and offers instructions into how to use them.
Certified diabetes educator Amy Hess-Fischl offers some guidance in determining how to incorporate a healthier diet.
The FDA recently approved Lucentis for use of diabetic retinopathy. Pharmacist and certified diabetes educator Sam Grossman talks about the clinical trial results for the new drug and considerations of how people with the complication may want to consider talking to their provider about it.
Diabetes educator Debbie Berg discusses some strategies to make it easier to keep up with your regular regimen of medicine.
The FDA approved the inhaled insulin, Afrezza, last summer, and it will likely undergo a massive marketing campaign to providers and possibly to people with diabetes directly. Here is some important clinical trial information about the medicine and how it is indicated for use in patients.
This app for adults or kids with type 2 is an interactive learning system with modules designed to teach people how to manage their diabetes.
Comfort, relaxation, may make you think of-massage. Is it advisable for people with diabetes to partake in this activity or is it Read more»
